SCHEMBL717093

SCHEMBL717093

Oc1cc[c]cc1C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.33
HSD17B2 P37059 2/20 0.33
AR P10275 4/20 0.32
PGR P06401 1/20 0.31
KIF11 P52732 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6758769 0.83
SCHEMBL1519797 0.82 AR (0.32) ARPGRKIF11
SCHEMBL146460 0.78 AR (0.31) AR
SCHEMBL225599 0.77 ALDH1A1 (0.48)
SCHEMBL14483362 0.76 GLA (0.38)
SCHEMBL27618380 0.74
SCHEMBL101627 0.74 KIF11 (0.32) KIF11
SCHEMBL145873 0.74 AR (0.32) AR
SCHEMBL14895318 0.74 KIF11 (0.33) ARKIF11
SCHEMBL9586467 0.73 APP (0.43) HSD17B1HSD17B2ARPGRKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140100194-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA, NV (BE) 2014-04-10 US claimed
US-8558011-B2 Cold menthol receptor-1 antagonists JANSSEN PHARMACEUTICA, NV (BE) 2013-10-15 US claimed
EP-2029614-B1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-01-23 EP claimed
US-20120053347-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-01 US claimed
US-20080287398-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 US claimed
US-20080027029-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-31 US claimed
US-20060025345-A1 Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-02-02 US claimed
WO-2005113582-A1 SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 WO claimed
CN-117586272-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2024-02-23 CN disclosed
CN-111615515-B Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2023-11-24 CN disclosed
CN-112979661-B Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技股份有限公司 2022-05-17 CN disclosed
CN-113396137-A Method for producing 1,1, 1-trifluoro-2, 2-bisarylethane, and 1,1, 1-trifluoro-2, 2-bisarylethane 中央硝子株式会社 2021-09-14 CN disclosed
CN-112979661-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技有限公司 2021-06-18 CN disclosed
CN-111615515-A Heterocyclic compound, preparation method and application thereof in medicine 苏州信诺维医药科技有限公司 2020-09-01 CN disclosed
US-4459405-A Desacetylcephalosporin sulfones ELI LILLY AND COMPANY (US) 1984-07-10 US disclosed
EP-0109816-A1 N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process ELI LILLY AND COMPANY (US) 1984-05-30 EP disclosed
EP-0109817-A2 Process for preparing oxazolinoazetidinones ELI LILLY AND COMPANY (US) 1984-05-30 EP disclosed
EP-0109301-A2 7-(S)-acylaminocephalosporin sulfones and process ELI LILLY AND COMPANY (US) 1984-05-23 EP disclosed
EP-0109300-A2 Desacetylcephalosporin sulfones ELI LILLY AND COMPANY (US) 1984-05-23 EP disclosed
US-4436596-A N-Substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process ELI LILLY AND COMPANY (US) 1984-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027029-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS TRPM8, TRPM5, TRPM7 HSD17B1 2127/4885HSD17B2 2674/4885AR 1496/4885
US-20060025345-A1 Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease PSEN1, PSEN2, APP HSD17B1 2195/4885HSD17B2 2252/4885AR 664/4885
US-20120053347-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS TRPM8, TRPM5, TRPM7 HSD17B1 2127/4885HSD17B2 2674/4885AR 1496/4885
US-20080287398-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS TRPM8, TRPM5, TRPM7 HSD17B1 2127/4885HSD17B2 2674/4885AR 1496/4885
US-20140100194-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS TRPM8, TRPM5, TRPM7 HSD17B1 2127/4885HSD17B2 2674/4885AR 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.